Skip to main content
Premium Trial:

Request an Annual Quote

Biomax Expands Agreement with Royal DSM to Include Synthetic Biology Solutions

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Biomax Informatics today said that it has expanded its licensing and services agreement with Royal DSM to include solutions for synthetic biology using the BioXM Knowledge Management Environment system.

BioXM is a software platform for dynamic modeling, visualization, and analysis of biological and biomedical networks. It enables an agile process for the development of new life sciences applications and the quick deployment of new solutions to large user communities, Biomax said.

Biomax and Royal DSM have been collaborating since 1998, and Royal DSM had early access to the next-generation BioXM system. BioXM version 4 was released in March and has a customizable web portal builder that enables quick publishing of BioXM-based application on the Internet.

Based in Planegg, Germany, Biomax develops software solutions for life science applications. Royal DSM is a life science and materials science firm headquartered in Heerlen, the Netherlands.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more